What Is the Target of Sunitinib 50 Mg

Sunitinib targets specific molecules involved in cancer cell growth and tumor progression. As a tyrosine kinase inhibitor (TKI), sunitinib inhibits the activity of several metabolic tyrosine kinases (RTKs), including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (KIT) in the ). By blocking these receptors, sunitinib disrupts signaling pathways that promote tumor angiogenesis (formation of new blood vessels) and cell proliferation, inhibiting cancer growth and progression This targeted pathway improves sunitinib in cancers including renal cell carcinoma (RCC), clinical stromal ( GIST) of tumors including the gastrointestinal tract, pancreatic neovascular tumor (pNET).